Table 2.
28-day cure results and pharmacodynamic parameters grouped according to age1 and parasite species
| Formulation | Adults (P. falciparum) | Adults (P. vivax) | Children (P. falciparum) |
|---|---|---|---|
| Number of patients | 28 | 10 | 47 |
| Total dose of dihydroartemisinin (mg kg–1) | 6.9 ± 0.9 | 6.9 ± 0.9 | 7.6 ± 1.6 |
| Total dose of piperaquine base (mg kg–1) | 31.9 ± 4.1 | 32.1 ± 4.2 | 34.9 ± 7.2 |
| Fever clearance times (h) | 12 (6–18) | 9 (6–12) | 12 (12–24) |
| Parasite clearance time (h) | NA2 | 12 (12–18) | NA2 |
| % patients with PCT ≤ 24 h | 71 | 100 | 85 |
| % patients PCT ≤ 48 h | 96 | 100 | 96 |
| % patients PCT ≤ 72 h | 100 | 100 | 100 |
| % of S/RI/RII/RIII | 96 (S) | 100 (S) | 98 (S) |
| % of ACPR/ETF/LCF/LPF3 | 96 (ACPR) | 100 (ACPR) | 98 (ACPR) |
1
Results as mean ± SD, or median and interquartile range
2
NA = not available as some patients had smears taken only every 24 h, and others 6 hourly
3
Adequate clinical parasitological response (ACPR), Early treatment failure (ETF), Late treatment failure-clinical (LCF), Late treatment failure- parasitological (LPF).